<DOC>
	<DOCNO>NCT02251223</DOCNO>
	<brief_summary>Primary : Sequentially determine effect three dose combination tipranavir ( TPV ) / ritonavir ( RTV ) ( administer b.i.d . ) , TPV 1250 mg/RTV 100 mg vs. TPV 750 mg/RTV 100 mg vs. TPV 250 mg/RTV 200 mg steady-state pharmacokinetics zidovudine , lamivudine , stavudine , didanosine , abacavir , nevirapine efavirenz approve dos . The three treatment group enrol sequentially start high tipranavir dosage group first end low tipranavir dosage group . Secondary : A ) To assess effect zidovudine , lamivudine , stavudine , didanosine , abacavir , nevirapine , efavirenz pharmacokinetics tipranavir/ritonavir compare historical control . B ) To assess safety three tipranavir/ritonavir combination use combination protocol define antiretrovirals .</brief_summary>
	<brief_title>Effects Tipranavir/Ritonavir Pharmacokinetic Characteristics Triple Drug Nucleoside Non-nucleoside Reverse Transcriptase Inhibitor Therapy HIV-1-infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>1 . Signed informed consent prior trial participation 2 . Between 18 75 year age inclusive 3 . Female subject child bear potential require use barrier contraceptive method least 12 week prior administration study medication , study medication administration , 28 day end study 4 . Ability swallow capsule without difficulty 5 . A Body Mass Index ( BMI ) 11 50 kg/m2 6 . Reasonable probability completion study 7 . Acceptable screen laboratory value . All laboratory value ≤ Grade I ( e.g. , creatine phosphokinase ( CPK ) , amylase , triglyceride ) permissible documentation stability 2 month available . Abnormalities &gt; Grade I subject approval BI clinical monitor designee 8 . Acceptable medical history , physical examination , ECG , chest Xray prior enter treatment phase study 9 . Willingness abstain alcohol Day 2 Day 23 10 . Willingness abstain ingest grapefruit , grapefruit juice , Seville oranges orange marmalade Day 2 Day 23 11 . Negative urine drug screen drug abuse . Subjects methadone equivalent narcotic maintenance program permit enter study 12 . Documented HIV1 RNA load ( PCR ) screen ≤20,000 copies/mL least twelve week . Acceptable documentation would include laboratory data , letter verbal report another provider note subject record . 13 . Stable dos approve NRTIs NNRTIs 2 minimum twelve week prior study Day 0 . Subjects efavirenz must able tolerate daily morning ( 8:00 a.m. ) dose start screening period 22 day study . Subjects receive bid ddI must willing accept change day delay release ( EC ) formulation 1 . Female subject : positive serum pregnancy test Screening Period Day 14 7 breast feeding 2 . Receipt investigational medicine 30 day prior Day 0 3 . Receipt known cytochrome P450 3A4 ( CYP3A4 ) alter drug i.e . phenothiazine , cimetidine , barbiturate , ketoconazole , fluconazole , rifampin , steroid herbal medication 30 day prior Day 0 . No antibiotic permit within 10 day prior Day 0 4 . Ingestion grapefruit , grapefruit juice , Seville oranges orange marmalade within 2 day study entry ( Day 0 ) 5 . Blood plasma donation ( &gt; 100 ml total ) research altruistic reason within 30 day prior Day 0 6 . Seated systolic blood pressure either &lt; 100 mm Hg &gt; 150 mm Hg ; rest heart rate either &lt; 50 beats/minute &gt; 90 beats/minute 7 . History illness , include malabsorption , irregular food intake gastrointestinal intolerance , allergy , opinion investigator , might confound result study pose additional risk administer TPV/RTV 8 . Any acute illness within 2 week prior Day 0 9 . Subjects currently take overthecounter drug within 7 day prior Day 0 , currently take prescription drug , opinion investigator ( consultation BI medical monitor and/or pharmacokineticist ) , might interfere either absorption , distribution metabolism TPV/RTV 10 . Hypersensitivity TPV , RTV sulfonamide contain drug 11 . Using adherence diary , subject less 100 % document adherence last 14 dos ( 7 day ) baseline antiretroviral medication prior Day 0 . Subjects less 100 % adherence last 7 dos ( 7 day ) efavirenz ddI ( delayed release ) prior Day 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>